Dr. Gottlieb is a physician scientist with a training in virology, genetics, and a PhD in chemistry and has helped lead transformative changes in multiple medical domains. He is in active clinical practice in advanced heart failure, mechanical circulatory support, and transplant cardiology. Together with his team, Dr. Gottlieb shared with the medical community the outcomes of the first heart transplant from a hepatitis C-infected donor to save the life of a non-infected heart transplant recipient in the era of the new, pangenotypic, direct-acting antivirals that promptly opened the door to increase available hearts for transplantation in the US by over 10 % per year. He has published at the forefront of genetically informed therapies for cardiomyopathy and polyneuropathy, including transthyretin-mediated amyloidosis. He has a special interest in real-world data analyses to complement randomized controlled trials.

During the SARS-CoV-2 pandemic, he applied his services to randomized clinical trials across the entire spectrum of Covid-19, from vaccines to outpatient use of antivirals including remdesivir and neutralizing monoclonal antibodies, to inpatient use of antivirals, immunomodulatory agents, and cellular-based investigational therapies. He has lectured internationally globally on a range of evidence-based therapies, informed by randomized controlled trials and complemented by real-world effectiveness studies.